CA2554216A1 - Methodes et compositions de traitement du cancer - Google Patents

Methodes et compositions de traitement du cancer Download PDF

Info

Publication number
CA2554216A1
CA2554216A1 CA002554216A CA2554216A CA2554216A1 CA 2554216 A1 CA2554216 A1 CA 2554216A1 CA 002554216 A CA002554216 A CA 002554216A CA 2554216 A CA2554216 A CA 2554216A CA 2554216 A1 CA2554216 A1 CA 2554216A1
Authority
CA
Canada
Prior art keywords
modified
megalin
metallothionein
composition according
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002554216A
Other languages
English (en)
Inventor
Bryan Klassen
Pierre J. Verroust
Patricia Allen
Timothy Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Tulane University
Xavier University of Louisiana
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2554216A1 publication Critical patent/CA2554216A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/825—Metallothioneins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002554216A 2004-01-23 2005-01-21 Methodes et compositions de traitement du cancer Abandoned CA2554216A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53871804P 2004-01-23 2004-01-23
US60/538,718 2004-01-23
PCT/US2005/002023 WO2005072270A2 (fr) 2004-01-23 2005-01-21 Methodes et compositions de traitement du cancer

Publications (1)

Publication Number Publication Date
CA2554216A1 true CA2554216A1 (fr) 2005-08-11

Family

ID=34826008

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002554216A Abandoned CA2554216A1 (fr) 2004-01-23 2005-01-21 Methodes et compositions de traitement du cancer

Country Status (3)

Country Link
EP (1) EP1711198A2 (fr)
CA (1) CA2554216A1 (fr)
WO (1) WO2005072270A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093177A2 (fr) 2006-02-14 2007-08-23 Vladimir Berezin Fragments de peptides derives de la metallothioneine
CN117285617B (zh) * 2023-09-28 2024-03-12 广州普言生物科技有限公司 一种重组金属硫蛋白Pro.MT及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083898A1 (fr) * 2001-04-18 2002-10-24 Genset S.A. Adn complementaires humains pleine longueur codant des proteines potentiellement secretees

Also Published As

Publication number Publication date
EP1711198A2 (fr) 2006-10-18
WO2005072270A2 (fr) 2005-08-11
WO2005072270A3 (fr) 2005-12-29

Similar Documents

Publication Publication Date Title
Yu et al. Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo
ES2613844T3 (es) Ligandos polidentados de alta afinidad selectivos y métodos para producirlos
AU2008296733B2 (en) VEGFR-1/NRP-1 targeting peptides
US9226952B2 (en) Na/K-ATPase-derived peptide Src inhibitors and ouabain antagonists and uses thereof
US20090227676A1 (en) Methods and compositions for treating cancer
US8658601B2 (en) Peptides and nanoparticles for therapeutic and diagnostic applications
US20060177452A1 (en) EphB receptor-binding peptides
US20220009991A1 (en) Bi-specific therapeutic proteins and method of use thereof
Ojeda et al. Lysine to arginine mutagenesis of chlorotoxin enhances its cellular uptake
WO2022192042A2 (fr) Régénération de tissus de mammifères à l'aide d'immodulines synthétiques
WO2019006690A1 (fr) Sel pharmaceutiquement acceptable d'un polypeptide et son application
US11541098B2 (en) Peptide composition for treating excitatory neurotoxicity related injuries
CA2554216A1 (fr) Methodes et compositions de traitement du cancer
CA3067457A1 (fr) Therapies ciblees
JP7166916B2 (ja) シスチンノットスキャフォールドプラットフォーム
US20200254110A1 (en) Ligand-conjugates and methods for targeted receptor-mediated cellular uptake
Nagai et al. Characterization of protamine uptake by opossum kidney epithelial cells
WO2023028486A1 (fr) Molécules de pénétration cellulaire spécifiques des leucocytes
WO2011133112A1 (fr) Peptide de pénétration cellulaire dérivé de la protéine pré-membranaire de flavivirus
Noh et al. Dimeric R25CPTH (1-34) Activates the Parathyroid Hormone-1 Receptor in vitro and Stimulates Bone Formation in Osteoporotic Female Mice
JP2010536858A (ja) エリスロポエチン受容体ペプチド製剤及び用途
US12122819B2 (en) Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant
US8420080B2 (en) Methods for treating adult respiratory distress syndrome
US20230287107A1 (en) Asic1 channel antagonist antibody
Kelly Delivery of Retinoic Acid Utilizing Cell Penetrating Peptides in Human Neuroblastoma Cells

Legal Events

Date Code Title Description
FZDE Discontinued